SPC1001 Low

DRUG2 trials

Sponsors

Shin Poong Pharmaceutical Co. Ltd.

Conditions

Diabete MellitusEssential HypertensionHypertensionHypertension (HTN)NYHA Class III Heart FailureNYHA Class IV Heart Failure

Phase 2

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

CompletedNCT06212648

Shin Poong Pharmaceutical Co. Ltd.Essential Hypertension, Hypertension

Start: 2022-03-25End: 2023-01-27Updated: 2024-01-19

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

Enrolling by invitationNCT07064525

Shin Poong Pharmaceutical Co. Ltd.Diabete Mellitus, Hypertension (HTN), NYHA Class III Heart Failure +1

Start: 2024-12-05End: 2026-02-28Target: 252Updated: 2025-07-14

Related Papers

Multicenter, Randomized, Double-Blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension.

2025-10-28